3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.

Core Industry Insights - The biotech industry is highlighted as a sector with significant potential for explosive revenue growth and innovative products, alongside AI and quantum computing [1][2] - Companies in biotech focus on cutting-edge technologies like gene editing and messenger RNA, which could lead to substantial long-term returns if their products reach commercialization [2] Company-Specific Analysis 1. Viking Therapeutics - Viking Therapeutics is developing VK2735, a weight loss drug, in both injectable and oral formats, with the injectable version entering phase 3 studies soon [4][5] - The weight loss drug market is projected to exceed $100 billion by the end of the decade, and Wall Street expects Viking's stock to rise by 250$1.9 billion, allowing it to continue developing its pipeline, with Wall Street forecasting an 87% increase in stock value over the next 12 months [14]